Literature DB >> 20974568

SEOM clinical guidelines for the treatment of Hodgkin's lymphoma.

Cristina Quero Blanco1, Ramón García Arroyo, Mariano Provencio Pulla, Antonio Rueda Domínguez, Dolores Isla Casado.   

Abstract

Hodgkin's lymphoma is a malignant disease with an incidence of 2.2 cases/100,000. The main goals of staging are to measure the extent of disease and associated prognostic factors. Distinct recommendations were produced for initial work-up, first-line therapy of early and advanced stage disease and treatment of relapsed or resistant patients.

Entities:  

Mesh：

Year:  2010        PMID： 20974568     DOI： 10.1007/s12094-010-0591-8

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


  15 in total

1.  MOPP versus ABVD and low-dose versus high-dose irradiation in Hodgkin's disease at intermediate and advanced stages: analysis of a meta-analysis by clinicians.

Authors:  J M Andrieu; U Yilmaz; P Colonna
Journal:  J Clin Oncol       Date:  1999-02       Impact factor: 44.544

2.  The EORTC trials for limited stage Hodgkin's disease. The EORTC Lymphoma Cooperative Group.

Authors:  J M Cosset; M Henry-Amar; J H Meerwaldt; P Carde; E M Noordijk; J Thomas; J M Burgers; R Somers; M Hayat; M Tubiana
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

3.  Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease.

Authors:  David J Straus; Carol S Portlock; Jing Qin; Jane Myers; Andrew D Zelenetz; Craig Moskowitz; Ariela Noy; André Goy; Joachim Yahalom
Journal:  Blood       Date:  2004-08-17       Impact factor: 22.113

4.  Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting.

Authors:  T A Lister; D Crowther; S B Sutcliffe; E Glatstein; G P Canellos; R C Young; S A Rosenberg; C A Coltman; M Tubiana
Journal:  J Clin Oncol       Date:  1989-11       Impact factor: 44.544

5.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

6.  Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial.

Authors:  D C Linch; D Winfield; A H Goldstone; D Moir; B Hancock; A McMillan; R Chopra; D Milligan; G V Hudson
Journal:  Lancet       Date:  1993-04-24       Impact factor: 79.321

7.  Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.

Authors:  Christophe Fermé; Houchingue Eghbali; Jacobus H Meerwaldt; Chantal Rieux; Jacques Bosq; Françoise Berger; Théodore Girinsky; Pauline Brice; Mars B van't Veer; Jan A Walewski; Pierre Lederlin; Umberto Tirelli; Patrice Carde; Eric Van den Neste; Emmanuel Gyan; Mathieu Monconduit; Marine Diviné; John M M Raemaekers; Gilles Salles; Evert M Noordijk; Geert-Jan Creemers; Jean Gabarre; Anton Hagenbeek; Oumédaly Reman; Michel Blanc; José Thomas; Brigitte Vié; Johanna C Kluin-Nelemans; Fernando Viseu; Joke W Baars; Philip Poortmans; Pieternella J Lugtenburg; Christian Carrie; Jérôme Jaubert; Michel Henry-Amar
Journal:  N Engl J Med       Date:  2007-11-08       Impact factor: 91.245

8.  Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin's disease.

Authors:  S Pavlovsky; M Maschio; M T Santarelli; F S Muriel; C Corrado; I Garcia; L Schwartz; C Montero; F L Sanahuja; O Magnasco
Journal:  J Natl Cancer Inst       Date:  1988-11-16       Impact factor: 13.506

9.  Involved-field radiotherapy for advanced Hodgkin's lymphoma.

Authors:  Berthe M P Aleman; John M M Raemaekers; Umberto Tirelli; Roberto Bortolus; Mars B van 't Veer; Marnix L M Lybeert; Jo J Keuning; Patrice Carde; Théodore Girinsky; Richard W M van der Maazen; Radka Tomsic; Marjeta Vovk; Achilles van Hoof; Geertrui Demeestere; Pieternella J Lugtenburg; José Thomas; Wilfried Schroyens; Koenraad De Boeck; Johanna W Baars; Johanna C Kluin-Nelemans; Christian Carrie; Malek Aoudjhane; Dominique Bron; Houchingue Eghbali; Wilma G J M Smit; Jacobus H Meerwaldt; Anton Hagenbeek; Antonella Pinna; Michel Henry-Amar
Journal:  N Engl J Med       Date:  2003-06-12       Impact factor: 91.245

10.  Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.

Authors:  Andreas Engert; Jeremy Franklin; Hans Theodor Eich; Corinne Brillant; Susanne Sehlen; Claudio Cartoni; Richard Herrmann; Michael Pfreundschuh; Markus Sieber; Hans Tesch; Astrid Franke; Peter Koch; Maike de Wit; Ursula Paulus; Dirk Hasenclever; Markus Loeffler; Rolf-Peter Müller; Hans Konrad Müller-Hermelink; Eckhart Dühmke; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-07-02       Impact factor: 44.544
View more
  2 in total

1.  The relevance of the Spanish Society for Medical Oncology (SEOM)'s clinical oncology guidelines.

Authors:  Dolores Isla Casado; Antonio González-Martín; Emilio Alba Conejo
Journal:  Clin Transl Oncol       Date:  2010-11       Impact factor: 3.405

2.  SEOM clinical guidelines for the treatment of Hodgkin's lymphoma.

Authors:  A Rueda Domínguez; J Alfaro Lizaso; L de la Cruz Merino; J Gumá I Padró; C Quero Blanco; J Gómez Codina; M Llanos Muñoz; N Martinez Banaclocha; D Rodriguez Abreu; M Provencio Pulla
Journal:  Clin Transl Oncol       Date:  2015-10-26       Impact factor: 3.405
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.